Vaxart, Inc. (VXRT) Form 8-K — Jun 26, 2026
$VXRTForm 8-KItems 1.01, 8.01, 9.01Filed Jun 26, 2026, 4:07 PM ET0001437749-26-021833Original filing
Vaxart entered into Modification No. 7 of its agreement with BARDA, reducing total available funding to approximately $345 million. This represents a decrease of roughly $116 million following a partial termination that resulted in a 50% reduction in trial participants. Despite the funding reduction, the modification allows for the release of approximately $29 million to complete the Phase 2b trial and conduct exploratory analyses.
Key figures
- Funding Decrease
- $116 million
- Firm Fixed Price Amount
- $68 million
- Release For Completion
- $29 million
- Total Funding Available
- $345 million
- Main Cohort Participants
- 5085
- Sentinel Cohort Participants
- 400
- Project Number
- 75A50123D00005
- Partial Termination Date
- August 5, 2025
- Participant Reduction Percentage
- 50%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.